Clinical Trial Update: A Study to Evaluate the Lipid Regulating Effects of TRIA-662 [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update notes the completion of Phase 2 and Phase 3 studies evaluating the lipid-lowering effects of TRIA-662 in hyperlipidemia. The sponsor of …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemia

Drugs mentioned

• TRIA-662

Snippet

Sponsor: Cortria Corporation | Conditions: Hyperlipidemia | Phase 2, Phase 3 | Status: COMPLETED